Nasal spray could replace needles for sickle cell pain emergencies

NCT ID NCT04076748

Terminated Symptom relief Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a nasal spray containing a strong painkiller (sufentanil) for adults with sickle cell disease experiencing a painful crisis. The goal was to see if it could provide faster relief than the standard gas mixture (EMONO) before giving morphine through an IV. The trial was stopped early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sufentanil (a strong painkiller given as a nasal spray)
What this could lead to: If it worked, this could offer a faster, needle-free way to ease severe sickle cell pain in the emergency room.
What could go wrong: The trial was terminated early, so results are limited. It is unclear if the nasal spray works better than the standard gas treatment, and strong painkillers carry risks like drowsiness or breathing problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL CRISIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agnosia sickle cell disease Vaso-Occlusive Crises

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SICKLE CELL CRISIS

Contacts and locations

Locations

CH de Cayenne

Cayenne, 97306, French Guiana
CHU Pointe à Pitre

Les Abymes, 97159, Guadeloupe
Gonesse Hospital

Gonesse, 95500, France
Hopital Pellegrin

Bordeaux, 33000, France
Hôpital Charles Nicolle

Rouen, 76031, France
Hôpital Edouard Herriot

Lyon, 69003, France
Hôpital Louis Mourier

Colombes, 92700, France
Hôpital Rangueil

Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.